Trial Profile
A trial to compare the treatment characteristics, survival and costs for sunitinib and pazopanib for advanced renal cell carcinoma (RCC) in a real-world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 03 Jun 2016 New trial record